Home › Compound Library › Celecoxib (Celebrex)

Celecoxib (Celebrex)

Analgesicprescriptionoral · predicted

Selective COX-2 inhibitor (coxib) NSAID. Provides anti-inflammatory and analgesic effects with significantly lower GI ulceration and bleeding risk than non-selective NSAIDs. Does not inhibit platelet aggregation (COX-1 sparing). Used for osteoarthritis, rheumatoid arthritis, acute pain, and familial adenomatous polyposis. CYP2C9 substrate — poor metabolizers have 3x higher exposure. Cardiovascular risk comparable to naproxen and ibuprofen per PRECISION trial.

Projected serum levels — 200 mg, twice daily

Celecoxib (Celebrex)
Celecoxib (Celebrex) modeled serum levels, 200 mg twice daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 2 days. 0 50 100 150 200 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 2
Celecoxib (Celebrex) modeled serum levels with a loading dose of 497 mg, then 200 mg twice daily The first dose is larger so levels approach steady state faster. 0 50 100 150 200 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 200 mg twice daily (oral).

Loading schedule: 497 mg on day 1, then 200 mg twice daily — reaching therapeutic levels sooner.

Modeled steady state after ~2 days: peak ≈ 156 mg, trough ≈ 113 mg body load. Population-based estimate over 15 days for a 200 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Analgesic
Route modeled
Oral
Model confidence
predicted
Half-life
11 h
Common dose
200 mg
Suggested maximum
400 mg/day
Reference dose range
100–400 mg (single dose)
Suggested cadence
twice daily
Validated against
200 mg oral — Cmax 0.70 mg/L at 3 h

Documented interactions

  • danger
    4-MMC (Mephedrone) + Celecoxib (Celebrex) CYP inhibition

    Celecoxib (Celebrex) reversible_inhibitor of CYP2D6 predicted to change 4-MMC (Mephedrone) AUC by ~2.27x

  • danger
    6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) + Celecoxib (Celebrex) CYP inhibition

    Celecoxib (Celebrex) reversible_inhibitor of CYP2D6 predicted to change 6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) AUC by ~3.33x

  • danger
    Amphetamine (Adderall) + Celecoxib (Celebrex) CYP inhibition

    Celecoxib (Celebrex) reversible_inhibitor of CYP2D6 predicted to change Amphetamine (Adderall) AUC by ~2.11x

  • danger
    Atomoxetine (Strattera) + Celecoxib (Celebrex) CYP inhibition

    Celecoxib (Celebrex) reversible_inhibitor of CYP2D6 predicted to change Atomoxetine (Strattera) AUC by ~2.68x

  • danger
    Carbamazepine (Tegretol) + Celecoxib (Celebrex) CYP induction

    Carbamazepine (Tegretol) inducer of CYP2C9 predicted to change Celecoxib (Celebrex) AUC by ~0.41x

  • danger
    CBD (Cannabidiol) + Celecoxib (Celebrex) CYP inhibition

    CBD (Cannabidiol) reversible_inhibitor of CYP2C9 predicted to change Celecoxib (Celebrex) AUC by ~2.97x

Serum checks 226 modeled interaction pairings for celecoxib (celebrex) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis (PRECISION trial) Nissen SE et al. · New England Journal of Medicine, 2016 DOI

    Landmark RCT (24,081 patients, 34 months) demonstrating celecoxib was non-inferior to naproxen and ibuprofen for cardiovascular safety, with significantly fewer GI and renal events, resolving decade-long safety concerns.

  2. Clinical pharmacology of celecoxib: a review Davies NM et al. · Clinical Pharmacokinetics, 2000 DOI

    PK review establishing celecoxib half-life of 11 hours, 40% bioavailability (increases with fat), CYP2C9 polymorphism effects (3x exposure in poor metabolizers), and 97% protein binding.

2 published studies referenced in the app, each with a plain-language summary.